Tokyo, Japan

Yumiko Osa


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:

goldMedal1 out of 94 
 
Pola Chemical Industries, Inc.
 patents
silverMedal1 out of 832,912 
Other
 patents
where one patent can have more than one assignee

Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yumiko Osa: Innovator in Drug-Resistance Overcoming Agents

Introduction

Yumiko Osa is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of medicinal chemistry, particularly in developing compounds that address drug resistance in diseases. Her innovative work has the potential to improve treatment outcomes for patients facing resistance-acquired conditions.

Latest Patents

Yumiko Osa holds a patent for "Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives." This patent includes dibenzosuberanyl piperazine derivatives represented by a specific formula, wherein R represents an aliphatic hydrocarbon group. These compounds are designed to restore sensitivity to drugs in resistance-acquired diseases, showcasing a resistance overcoming effect. The patent highlights the effectiveness of these derivatives and their physiologically acceptable salts in medicinal compositions.

Career Highlights

Throughout her career, Yumiko Osa has worked with notable companies, including Pola Chemical Industries, Inc. Her research and development efforts have focused on creating innovative solutions to combat drug resistance, making her a key figure in her field.

Collaborations

Yumiko has collaborated with esteemed colleagues such as Tsutomu Takeuchi and Hiroaki Takayanagi. These partnerships have furthered her research and contributed to the advancement of her patented technologies.

Conclusion

Yumiko Osa's work in developing drug-resistance overcoming agents represents a significant advancement in medicinal chemistry. Her innovative contributions continue to pave the way for improved treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…